Astria Therapeutics
About Company
Astria Therapeutics is a biopharmaceutical company focused on developing and delivering life-changing therapies for patients with allergic and immunological diseases. Their pipeline includes Navenibart, a monoclonal antibody inhibitor of plasma kallikrein in clinical development for hereditary angioedema, and STAR-0310, an OX40 monoclonal antibody antagonist in pre-clinical development for atopic dermatitis and other similar diseases. The company emphasizes a patient-first, people-always culture and is committed to building a diverse and inclusive workplace.
